市場調查報告書

生殖器皰疹:市場考察,流行病學及市場預測

Genital Herpes - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 602062
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
生殖器皰疹:市場考察,流行病學及市場預測 Genital Herpes - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

本報告涵括全球生殖器皰疹 (GH) 市場,從病因,症狀,分類,病理學,診斷及治療模式的說明,來提供生殖器皰疹的詳細概要,並彙整未滿足需求,上市藥·新藥的簡介,主要7個市場患者數的實際成果·預測·展望等資料。

第1章 主要考察

第2章 生殖器皰疹 (GH) 市場概要

  • 生殖器皰疹的市場佔有率分佈 (%) :2017年
  • 生殖器皰疹的市場佔有率分佈 (%) :2027年

第3章 疾病的背景和概要:生殖器皰疹 (GH)

  • 簡介
  • 病理學
  • 病因
  • 風險要素
  • 併發症
  • 症狀
  • 臨床症狀
  • 診斷

第4章 流行病學和患者人口

  • 主要調查結果
  • 疾病定義
  • 患者人口與預測參數
  • 主要7個國家 (7MM)的生殖器皰疹患者人口

第5章 各國生殖器皰疹 (PAH) 流行病學

  • 美國
    • 患者人口
    • 性別的患者人口
    • 診斷案例總數
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 日本

第6章 目前治療·醫療行為

  • HIV感染患者藥物抗性性器官單純皰疹病毒感染的治療
  • 治療指南
    • CDC (美國疾病管理預防中心)
    • WHO (世界衛生組織)
    • 歐洲指南

第7章 未滿足需求

第8章 上市藥

  • Famvir: Novartis
    • 藥物的說明
    • 其他開發活動
    • 法規里程碑
    • 優點及缺點
    • 安全性·功效
    • 產品簡介
  • Valtrex: GlaxoSmithKline
  • Zovirax: GlaxoSmithKline

第9章 新藥

  • GEN 003: Genocea Biosciences
  • Pritelivir: AiCuris
  • VCL-HB01: Vical
  • M5210B: Maruho

第10章 生殖器皰疹:主要7個市場分析

  • 主要7個市場的生殖器皰疹的市場規模
  • 生殖器皰疹市場:各治療類型
  • 生殖器皰疹的新興治療市場

第11章 市場展望:各國

  • 美國:市場展望
  • EU5個國家:市場展望
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 義大利
  • 日本:市場展望

第12章 市場成長的促進要素

第13章 市場障礙

第14章 附錄

第15章 DelveInsight的服務內容

第16章 免責聲明

第17章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0287

DelveInsight's "Genital Herpes - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Genital Herpes, historical and forecasted epidemiology as well as the Genital Herpes market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Genital Herpes market report provides current treatment practices, emerging drugs, Genital Herpes market share of the individual therapies, current and forecasted Genital Herpes market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Genital Herpes treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Genital Herpes Disease Understanding and Treatment Algorithm

The DelveInsight Genital Herpes market report gives a thorough understanding of the Genital Herpes by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Genital Herpes.

Treatment

It covers the details of conventional and current medical therapies available in the Genital Herpes market for the treatment of the condition. It also provides Genital Herpes treatment algorithms and guidelines in the United States, Europe, and Japan.

Genital Herpes Epidemiology

The Genital Herpes epidemiology division provide insights about historical and current Genital Herpes patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Genital Herpes epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Genital Herpes Epidemiology

The epidemiology segment also provides the Genital Herpes epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Genital Herpes Drug Chapters

Drug chapter segment of the Genital Herpes report encloses the detailed analysis of Genital Herpes marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Genital Herpes clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Genital Herpes treatment.

Genital Herpes Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Genital Herpes treatment.

Genital Herpes Market Outlook

The Genital Herpes market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Genital Herpes market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Genital Herpes market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Genital Herpes market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Genital Herpes market in 7MM.

The United States Market Outlook

This section provides the total Genital Herpes market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Genital Herpes market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Genital Herpes market size and market size by therapies in Japan is also mentioned.

Genital Herpes Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Genital Herpes market or expected to get launched in the market during the study period 2017-2030. The analysis covers Genital Herpes market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Genital Herpes Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Genital Herpes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Genital Herpes emerging therapies.

Reimbursement Scenario in Genital Herpes

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Genital Herpes domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Genital Herpes market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Genital Herpes Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Genital Herpes, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Genital Herpes epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Genital Herpes are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Genital Herpes market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Genital Herpes market

Report Highlights

  • In the coming years, Genital Herpes market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Genital Herpes R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Genital Herpes. Launch of emerging therapies will significantly impact the Genital Herpes market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Genital Herpes
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Genital Herpes Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Genital Herpes Pipeline Analysis
  • Genital Herpes Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Genital Herpes Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Genital Herpes Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Genital Herpes Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Genital Herpes market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Genital Herpes total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Genital Herpes market size during the forecast period (2017-2030)?
  • At what CAGR, the Genital Herpes market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Genital Herpes market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Genital Herpes market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Genital Herpes?
  • What is the historical Genital Herpes patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Genital Herpes in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Genital Herpes?
  • Out of all 7MM countries, which country would have the highest prevalent population of Genital Herpes during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Genital Herpes treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Genital Herpes in the USA, Europe, and Japan?
  • What are the Genital Herpes marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Genital Herpes?
  • How many therapies are developed by each company for Genital Herpes treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Genital Herpes treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Genital Herpes therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Genital Herpes and their status?
  • What are the key designations that have been granted for the emerging therapies for Genital Herpes?
  • What are the global historical and forecasted market of Genital Herpes?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Genital Herpes market
  • To understand the future market competition in the Genital Herpes market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Genital Herpes in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Genital Herpes market
  • To understand the future market competition in the Genital Herpes market

Table of Contents

1. Key Insights

2. Executive Summary of Genital Herpes

3. Competitive Intelligence Analysis for Genital Herpes

4. Genital Herpes: Market Overview at a Glance

  • 4.1. Genital Herpes Total Market Share (%) Distribution in 2017
  • 4.2. Genital Herpes Total Market Share (%) Distribution in 2030

5. Genital Herpes: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Genital Herpes Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Genital Herpes Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Genital Herpes Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Genital Herpes Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Genital Herpes Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Genital Herpes Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Genital Herpes Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Genital Herpes Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Genital Herpes Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Genital Herpes Treatment and Management
  • 8.2. Genital Herpes Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Genital Herpes Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Genital Herpes: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Genital Herpes Market Size in 7MM
  • 13.3. Genital Herpes Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Genital Herpes Total Market Size in the United States
    • 15.1.2. Genital Herpes Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Genital Herpes Total Market Size in Germany
    • 15.3.2. Genital Herpes Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Genital Herpes Total Market Size in France
    • 15.4.2. Genital Herpes Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Genital Herpes Total Market Size in Italy
    • 15.5.2. Genital Herpes Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Genital Herpes Total Market Size in Spain
    • 15.6.2. Genital Herpes Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Genital Herpes Total Market Size in the United Kingdom
    • 15.7.2. Genital Herpes Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Genital Herpes Total Market Size in Japan
    • 15.8.3. Genital Herpes Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Genital Herpes

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Genital Herpes Epidemiology (2017-2030)
  • Table 2 : 7MM Genital Herpes Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Genital Herpes Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Genital Herpes Epidemiology in Germany (2017-2030)
  • Table 6 : Genital Herpes Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Genital Herpes Epidemiology in France (2017-2030)
  • Table 8 : Genital Herpes Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Genital Herpes Epidemiology in Italy (2017-2030)
  • Table 10 : Genital Herpes Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Genital Herpes Epidemiology in Spain (2017-2030)
  • Table 12 : Genital Herpes Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Genital Herpes Epidemiology in the UK (2017-2030)
  • Table 14 : Genital Herpes Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Genital Herpes Epidemiology in Japan (2017-2030)
  • Table 16 : Genital Herpes Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Genital Herpes Epidemiology (2017-2030)
  • Figure 2 : 7MM Genital Herpes Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Genital Herpes Epidemiology in the United States (2017-2030)
  • Figure 4 : Genital Herpes Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Genital Herpes Epidemiology in Germany (2017-2030)
  • Figure 6 : Genital Herpes Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Genital Herpes Epidemiology in France (2017-2030)
  • Figure 8 : Genital Herpes Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Genital Herpes Epidemiology in Italy (2017-2030)
  • Figure 10 : Genital Herpes Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Genital Herpes Epidemiology in Spain (2017-2030)
  • Figure 12 : Genital Herpes Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Genital Herpes Epidemiology in the UK (2017-2030)
  • Figure 14 : Genital Herpes Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Genital Herpes Epidemiology in Japan (2017-2030)
  • Figure 16 : Genital Herpes Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)